HC Wainwright Issues Pessimistic Outlook for CRVS Earnings

Corvus Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its earnings outlook, lowering Corvus Pharmaceuticals’ FY2026 forecast to a loss of $0.86 per share from $0.83; it also projects losses in FY2027–FY2029, with a return to profit in FY2030.
  • Corvus reported a quarterly loss of $0.22 per share, missing analyst expectations of a $0.19 loss by $0.03.
  • Analyst views remain mixed: MarketBeat’s consensus rating is “Moderate Buy,” with an average price target of $32.83.
  • MarketBeat previews the top five stocks to own by December 1st.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Investment analysts at HC Wainwright lowered their FY2026 earnings estimates for Corvus Pharmaceuticals in a research note issued on Wednesday, November 11th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of ($0.86) for the year, down from their prior estimate of ($0.83). The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals' Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.26) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at ($0.90) EPS, FY2029 earnings at ($0.43) EPS and FY2030 earnings at $0.45 EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03).

A number of other equities analysts also recently weighed in on the stock. Ladenburg Thalmann & Co. Inc. upgraded shares of Corvus Pharmaceuticals to a "strong-buy" rating in a report on Thursday, July 30th. Wall Street Zen lowered shares of Corvus Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, November 7th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Corvus Pharmaceuticals in a report on Wednesday, September 16th. Mizuho set a $27.00 price objective on Corvus Pharmaceuticals in a research note on Thursday, October 29th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Corvus Pharmaceuticals in a research note on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $32.83.

Read Our Latest Stock Report on CRVS

Corvus Pharmaceuticals Stock Performance

NASDAQ:CRVS opened at $10.62 on Friday. The stock's 50-day simple moving average is $11.26 and its 200 day simple moving average is $14.10. The company has a market cap of $895.80 million, a P/E ratio of -14.96 and a beta of 1.57. Corvus Pharmaceuticals has a 52-week low of $6.39 and a 52-week high of $26.95.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company lifted its position in Corvus Pharmaceuticals by 481.7% during the first quarter. The Manufacturers Life Insurance Company now owns 101,779 shares of the company's stock worth $1,489,000 after purchasing an additional 84,282 shares during the period. DCF Advisers LLC acquired a new stake in Corvus Pharmaceuticals during the second quarter worth about $9,524,000. Blue Owl Capital Holdings LP acquired a new stake in Corvus Pharmaceuticals during the second quarter worth about $9,092,000. Renaissance Technologies LLC bought a new position in Corvus Pharmaceuticals in the 1st quarter valued at about $1,190,000. Finally, Bank of America Corp DE bought a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $11,322,000. Institutional investors own 46.64% of the company's stock.

Key Stories Impacting Corvus Pharmaceuticals

Investors following CRVS have been watching these stories:

  • Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple periods, including FY2026 to a loss of $0.86 per share from $0.83, FY2027 to a loss of $1.04 from $0.80, and FY2028 to a loss of $0.90 from $0.37. Estimates for several 2027 quarters were also cut. Its FY2030 forecast still implies a profit, but was reduced to $0.45 per share from $0.67. The broad revisions point to weaker expected earnings and a longer path to profitability. Corvus Pharmaceuticals analyst estimates

Corvus Pharmaceuticals Company Profile

(Get Free Report)

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.

See Also

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?

Before you consider Corvus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.

While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines